Instructor
John E Lincoln
The artificial intelligence technologies granted FDA marketing authorization and cleared by the Agency are generally called “locked” algorithms that don’t continually adapt or learn every time the algorithm is used.
However, the FDA is now focusing on those capable of true AI, - machine learning algorithms that continually evolve, often called “adaptive” or “continuously learning” algorithms. Adaptive algorithms can learn from new user data presented to the algorithm through real-world use. The FDA is allowing modifications to algorithms to be made from real-world learning and adaptation, while still ensuring safety and effectiveness of the software as a medical device (SaMD) is maintained, without requiring frequent updates or submissions.
This webinar will discuss information specific to devices that include artificial intelligence algorithms that make real-world modifications that the Agency would require for premarket review. They include the algorithm’s performance, the added concerns for AI / ML software Verification and Validation, the manufacturer’s plan for modifications and the ability of the manufacturer to manage and control risks of the modifications, including the software’s "predetermined change control plan" (PCCP). It will also address using AI to assist in preparing the 510(k) submission documentation for such applications.
The US FDA has defined the steps needed for the regulatory framework for the development of safe and effective medical devices that use advanced artificial intelligence / machine learning algorithms. Artificial intelligence algorithms are software that can learn from and act on data.
The authorization of these technologies was a harbinger of progress that the FDA expects to see as more medical devices incorporate advanced artificial intelligence algorithms to improve their performance and safety. Since AI changes over time, how will the Agency control these changes without requiring newmarketing submissions. AI software validation has some new requirements as well. Industry can use AI to safely speed up the preparation and documentation of company product 510(k) submissions to the Agency as well, which will also be considered in this webinar.
This webinar will provide valuable assistance to all regulated companies in evaluating their existing or anticipated AI medical device R&D and production activities and documentation requirements, as currently anticipated by the US FDA. This information applies to personnel / companies in the Medical Device and some Combination products fields. The employees who will benefit include:
All personnel involved in a U.S. FDA-regulated environment. Especially those involved in new product development with products and productioin / test equipment that are software driven, companies with quality management / MRP / ERP systems moving toward "paperless systems, or other regulated medical products / CGMP, ISO QMS, and submission activities.
